Transient Ablation of Regulatory T cells Improves Antitumor Immunity in Colitis-Associated Colon Cancer
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Regulatory T cells (Treg) are supportive to cancer development in most tissues, but their role in colitis-associated colon cancer (CAC) remains unclear. In this study, we investigated the role of CD4+Foxp3+ Treg in a mouse model of CAC and in patients with colon cancer. These Treg were increased strongly in number in a mouse model of CAC and in the peripheral blood of patients with colon cancer, exhibiting an activated phenotype as defined by elevated expression of GARP, CD103, CTLA-4, and IL10, along with an increased suppressive effect on the proliferation and Th1 cytokine expression of CD4+CD25− responder T cells ex vivo. Transient ablation of CD4+Foxp3+ Treg during tumor development in the CAC model suppressed tumor outgrowth and distribution, accompanied by an increased number of CD8+IFNγ/granzyme B-producing effector T cells. Conversely, inactivation of IL10 in Treg did not elevate the antitumor response but instead further boosted tumor development. Our results establish a tumor-promoting function for Treg during CAC formation, but they also suggest that a selective, transient ablation of Treg can evoke antitumor responses, with implications for immunotherapeutic interventions in patients with CAC. Cancer Res; 74(16); 4258–69. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Unravelling the pathogenesis of inflammatory bowel disease
Xavier, R. J., & Podolsky, D. K. (2007) · Nature · doi:10.1038/nature06005 · Cited by 4,364
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
Self-citationIKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
Role of cytokines in inflammatory bowel disease
Sanchez-Muñoz, F., Dominguez-Lopez, A., & Yamamoto-Furusho, J. K. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.4280 · Cited by 699
Powrie, F., Correa-Oliveira, R., Mauze, S., & Coffman, R. L. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.2.589 · Cited by 613
Granzymes in cancer and immunity
Cullen, S. P., Brunet, M., & Martin, S. J. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.206 · Cited by 391
High resolution colonoscopy in live mice
Becker, C., Fantini, M. C., & Neurath, M. F. (2006) · Nature Protocols · doi:10.1038/nprot.2006.446 · Cited by 369
High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas
Le Gouvello, S., Bastuji-Garin, S., Aloulou, N., Mansour, H., Chaumette, M.-T., Berrehar, F., Seikour, A., Charachon, A., Karoui, M., Leroy, K., et al. (2008) · Gut · doi:10.1136/gut.2007.123794 · Cited by 214
CD4+CD25+ Regulatory Lymphocytes Induce Regression of Intestinal Tumors in ApcMin/+ Mice
Erdman, S. E., Sohn, J. J., Rao, V. P., Nambiar, P. R., Ge, Z., Fox, J. G., & Schauer, D. B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3104 · Cited by 211
Cited by
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
Plitas, G., Konopacki, C., Wu, K., Bos, P. D., Morrow, M., Putintseva, E. V., Chudakov, D. M., & Rudensky, A. Y. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.032 · Cited by 695
“It is thought that Treg cells can facilitate tumor growth and metastasis based on the observed regression of established tumors in experimental models of Treg cell depletion ( Joshi et al., 2015; Klages et al., 2010; Pastille et al., 2014; Teng et al., 2010).”
Targeting Treg cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2019) · European Journal of Immunology · doi:10.1002/eji.201847659 · Cited by 476
Self-citationImmunosuppression associated with chronic inflammation in the tumor microenvironment
Wang, D., & DuBois, R. N. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv123 · Cited by 355
From mice to humans: developments in cancer immunoediting
Teng, M. W. L., Galon, J., Fridman, W.-H., & Smyth, M. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80004 · Cited by 337
“It may reflect the heterogeneity of Treg subsets (96) in the tumor microenvironment or the selectivity of Treg markers (97).”
BackgroundUribe-Herranz, M., Rafail, S., Beghi, S., Gil-de-Gómez, L., Verginadis, I., Bittinger, K., Pustylnikov, S., Pierini, S., Perales-Linares, R., Blair, I. A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124332 · Cited by 316
“catalog BE0117) or rat IgG2b isotype control (InVivoMAb LTF-2, BioXCell, catalog BE0090) by intraperitoneal injection (37).”
Background
Metadata
- Authors
- Pastille, E., Bardini, K., Fleissner, D., Adamczyk, A., Frede, A., Wadwa, M., von Smolinski, D., Kasper, S., Sparwasser, T., Gruber, A. D., Schuler, M., Sakaguchi, S., Roers, A., Müller, W., Hansen, W., Buer, J., & Westendorf, A. M.
- Venue
- Cancer Research
- Published
- 2014-08-13
- Volume
- 74
- Issue
- 16
- Pages
- 4258-4269
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2147286906
- Cited by
- 101
- References
- 9
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Transient Ablation of Regulatory T cells Improves Antitumor Immunity in Colitis-Associated Colon Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-13-3065
- The paper
- Pastille, E., Bardini, K., Fleissner, D., Adamczyk, A., Frede, A., Wadwa, M., von Smolinski, D., Kasper, S., Sparwasser, T., Gruber, A. D., Schuler, M., Sakaguchi, S., Roers, A., Müller, W., Hansen, W., Buer, J., & Westendorf, A. M. (2014). Transient Ablation of Regulatory T cells Improves Antitumor Immunity in Colitis-Associated Colon Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-13-3065
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.